Marinus Pharmaceuticals Stock Filter Stocks by Fundamentals
| MRNS Stock | USD 0.33 0.01 3.13% |
Marinus Pharmaceuticals fundamentals help investors to digest information that contributes to Marinus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Marinus Stock. The fundamental analysis module provides a way to measure Marinus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marinus Pharmaceuticals stock.
Marinus | Shares Owned by Institutions |
Marinus Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Marinus Pharmaceuticals from analyzing Marinus Pharmaceuticals' financial statements. These drivers represent accounts that assess Marinus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Marinus Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 117.4M | 117.7M | 436.0M | 155.5M | 584.2M | 613.4M | |
| Enterprise Value | 49.6M | 27.3M | 353.8M | (12.4M) | 574.0M | 602.7M |
Marinus Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Marinus Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Marinus Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Marinus Pharmaceuticals' value.| Shares | Millennium Management Llc | 2024-06-30 | 718.6 K | Ikarian Capital, Llc | 2024-09-30 | 706.2 K | Lion Point Capital, Lp | 2024-09-30 | 693.8 K | Goldman Sachs Group Inc | 2024-06-30 | 582.1 K | Geode Capital Management, Llc | 2024-09-30 | 568.5 K | Renaissance Technologies Corp | 2024-09-30 | 501.9 K | Susquehanna International Group, Llp | 2024-06-30 | 501.8 K | Assenagon Asset Management Sa | 2024-09-30 | 444.2 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 414.3 K | Franklin Resources Inc | 2024-09-30 | 4.7 M | Tang Capital Management Llc | 2024-09-30 | 4.7 M |
Marinus Fundamentals
| Return On Equity | -29.87 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (3.76) % | ||||
| Current Valuation | 31.74 M | ||||
| Shares Outstanding | 55.19 M | ||||
| Shares Owned By Insiders | 10.94 % | ||||
| Shares Owned By Institutions | 83.03 % | ||||
| Number Of Shares Shorted | 5.66 M | ||||
| Price To Earning | (4.80) X | ||||
| Price To Book | 3.17 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 30.99 M | ||||
| Gross Profit | (55.94 M) | ||||
| EBITDA | (125.5 M) | ||||
| Net Income | (141.41 M) | ||||
| Cash And Equivalents | 168.25 M | ||||
| Cash Per Share | 4.52 X | ||||
| Total Debt | 110.36 M | ||||
| Debt To Equity | 0.88 % | ||||
| Current Ratio | 8.41 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (118 M) | ||||
| Short Ratio | 1.09 X | ||||
| Earnings Per Share | (2.47) X | ||||
| Target Price | 1.47 | ||||
| Number Of Employees | 165 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 17.94 M | ||||
| Total Asset | 170.91 M | ||||
| Retained Earnings | (571.93 M) | ||||
| Working Capital | 124.62 M | ||||
| Current Asset | 57.77 M | ||||
| Current Liabilities | 7.43 M | ||||
| Net Asset | 170.91 M |
About Marinus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marinus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marinus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marinus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.